Wanbury Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹183 Cr +14.4% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
W

Wanbury Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Wanbury Q1 FY27: Revenue ₹164.58 Cr, PAT ₹21.70 Cr

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹166Cr
+1.8% YoY
+0.6% QoQ
Net profit
₹3Cr
−76.9% YoY
−86.4% QoQ
Margin
10%
−5 pp YoY
−8 pp QoQ

Based on Wanbury Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹224
Market cap₹779 Cr
P/E13.1

The short version

Q4FY26 Revenue from Operations: ₹164.58 Crore - Year-on-Year (YoY) change: +1% - Q4FY26 API Revenue: ₹144 Crore - YoY change: -4% - FY26 Total Revenue from Operations: ₹650.26 Crore - YoY change: +8% (from ₹599.51 Crore in FY25) - FY26 API Revenue: ₹574 Crore - YoY growth: 8% - FY26 Formulations Revenue: ₹76 Crore - Management Commentary notes a revenue decline in Q4 due to West Asia crisis impacting API exports in March but states growth expected from new product launches in Q4. EBITDA for Q4FY26: ₹30.06 Crore, with a year-on-year (YoY) growth of 12% - EBITDA Margin for Q4FY26: 18.3%, up by 173 basis points (BPS) YoY - Profit After Tax (PAT) for Q4FY26: ₹21.70 Crore, with YoY growth of 38% - PAT Margin for Q4FY26: 13.19%, up by 349 BPS YoY

From Wanbury Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q4FY26 Revenue from Operations: ₹164.58 Crore
  • Year-on-Year (YoY) change: +1%
  • Q4FY26 API Revenue: ₹144 Crore
  • YoY change: -4%
  • FY26 Total Revenue from Operations: ₹650.26 Crore
  • YoY change: +8% (from ₹599.51 Crore in FY25)
  • FY26 API Revenue: ₹574 Crore
  • YoY growth: 8%
  • FY26 Formulations Revenue: ₹76 Crore
  • Management Commentary notes a revenue decline in Q4 due to West Asia crisis impacting API exports in March but states growth expected from new product launches in Q4.
  • Outlook:

2 more points from Wanbury Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Wanbury Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Upcoming 1.5 MW solar energy project at Satara site to meet 70% of Patalganga site’s energy needs through renewable energy (Page 12).
  • Brownfield expansion planned for operational scale-up and margin expansion (Page 5).
  • Future reactor capacity potential at existing sites: 600 KL (current capacity 500 KL) indicating planned capacity expansion (Page 15).

2 more points from Wanbury Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Wanbury Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Wanbury Ltd said on order book & pipeline — free account, 30 seconds.

Wanbury Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Wanbury Ltd Q1 FY27 results — key figures

Wanbury Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue166163+1.8%165+0.6%
Operating profit (EBITDA)1624-33.3%30-46.7%
Operating margin10%15%-5 pp18%-8 pp
Profit before tax514-64.3%15-66.7%
Net profit (PAT)313-76.9%22-86.4%
EPS (₹)0.934.10-77.3%6.21-85%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹183 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Wanbury Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Wanbury Ltd Q1 FY27 results?

Q4FY26 Revenue from Operations: ₹164.58 Crore - Year-on-Year (YoY) change: +1% - Q4FY26 API Revenue: ₹144 Crore - YoY change: -4% - FY26 Total Revenue from Operations: ₹650.26 Crore - YoY change: +8% (from ₹599.51 Crore in FY25) - FY26 API Revenue: ₹574 Crore - YoY growth: 8% - FY26 Formulations Revenue: ₹76 Crore - Management Commentary notes a revenue decline in Q4 due to West Asia crisis impacting API exports in March but states growth expected from new product launches in Q4. EBITDA for Q4FY26: ₹30.06 Crore, with a year-on-year (YoY) growth of 12% - EBITDA Margin for Q4FY26: 18.3%, up by 173 basis points (BPS) YoY - Profit After Tax (PAT) for Q4FY26: ₹21.70 Crore, with YoY growth of 38% - PAT Margin for Q4FY26: 13.19%, up by 349 BPS YoY

What is Wanbury Ltd share price analysis?

Wanbury Ltd currently shows a neutral. The stock trades at a P/E of 13.1 with a market cap of ₹779 Cr. Investors should review the full earnings analysis for detailed insights.

Is Wanbury Ltd planning capital expenditure?

Upcoming 1.5 MW solar energy project at Satara site to meet 70% of Patalganga site’s energy needs through renewable energy (Page 12).

Keep Wanbury Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.